Skip to Content
Merck
CN

Y0000726

Dorzolamide hydrochloride

European Pharmacopoeia (EP) Reference Standard

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C10H16N2O4S3 · HCl
CAS Number:
130693-82-2
Molecular Weight:
360.90
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
329831117
MDL number:
MFCD00884659
Beilstein/REAXYS Number:
5896026

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Dorzolamide hydrochloride, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C10H16N2O4S3.ClH/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16;/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16);1H/t6-,8-;/m0./s1

SMILES string

Cl.CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O

InChI key

OSRUSFPMRGDLAG-QMGYSKNISA-N

grade

pharmaceutical primary standard

API family

dorzolamide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... CA2(760)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Dorzolamide hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

hcodes

H302,H373

Hazard Classifications

Acute Tox. 4 Oral - STOT RE 2

target_organs

Central nervous system,Gastrointestinal tract,Bone,Blood,Bladder

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mohamed A Genead et al.
Retina (Philadelphia, Pa.), 32(4), 826-833 (2011-09-03)
: To determine the value of a topical carbonic anhydrase inhibitor on the macular thickness and function in choroideremia patients with cystoid macular edema. : Two choroideremia patients with cystoid macular edema, observed by spectral-domain optical coherence tomography, were treated
Aukje van Gestel et al.
Acta ophthalmologica, 90(1), 20-31 (2012-02-01)
To evaluate the long-term effects and costs of four treatment strategies for primary open-angle glaucoma compared to usual care. Cost-effectiveness analyses with a lifelong horizon were made from a societal perspective. Data were generated with a patient-level model based on
Mumin Hakan Eren et al.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 28(4), 381-386 (2012-02-11)
To compare the efficacy and safety of dorzolamide hydrochloride 2%/timolol maleate 0.5% fixed combination (DTFC) with latanoprost 0.005%/timolol maleate 0.5% fixed combination (LTFC) on diurnal intraocular pressure (IOP) in patients with primary open-angle glaucoma. Thirty-three primary open-angle glaucoma patients with
Kelly J Sigle et al.
Veterinary ophthalmology, 14 Suppl 1, 48-53 (2011-09-23)
To determine the extent of fluctuation in circadian intraocular pressure (IOP) and the efficacy of topical dorzolamide 2% q 8 h in lowering IOP and blunting circadian fluctuation in IOP in glaucomatous cats. Seven adult cats with primary congenital glaucoma
Ikuyo Ohguro et al.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 28(4), 392-396 (2012-04-07)
The purpose of the present study is to evaluate the effects of a fixed combination of 0.5% timolol maleate (TM) and 1% dorzolamide hydrochloride (DZ) (FCTD(1%)) on optic nerve head (ONH) blood circulation. A drop of 0.5% TM, 1% DZ
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service